Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide.
| Revenue (TTM) | $9.94B |
| Gross Profit (TTM) | $7.82B |
| EBITDA | $3.54B |
| Operating Margin | 22.90% |
| Return on Equity | 7.70% |
| Return on Assets | 5.95% |
| Revenue/Share (TTM) | $67.70 |
| Book Value | $126.37 |
| Price-to-Book | 1.58 |
| Price-to-Sales (TTM) | 3.06 |
| EV/Revenue | 3.203 |
| EV/EBITDA | 11.79 |
| Quarterly Earnings Growth (YoY) | 31.10% |
| Quarterly Revenue Growth (YoY) | 1.90% |
| Shares Outstanding | $147.64M |
| Float | $147.18M |
| % Insiders | 0.19% |
| % Institutions | 96.41% |
Volatility is currently contracting
Pre-market futures are flat-to-down ahead of today's open, with overseas turbulence in the memory chip market reverberating on domestic shores. We also see something of a hesitation in trading ahead of this afternoon's Fed decision on interest rates.
Biogen tops Q2 earnings and revenue estimates as growth drugs fuel sales, offset MS declines, and support a higher 2026 revenue and EPS outlook.
A quarter-points rate hike has been bandied about as a possibility today.
Biogen Inc. is upgraded to 'Buy' as strategic acquisitions and pipeline progress offset multiple sclerosis portfolio erosion. Q2 revenue grew 3% Y/Y, aided by Apellis acquisition, rare disease, and Alzheimer's collaboration, with LEQEMBI gaining global traction. Felzartamab's multi-indication potential and upcoming pivotal trial readouts underpin BIIB's long-term growth prospects.
Although the revenue and EPS for Biogen (BIIB) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Biogen NASDAQ: BIIB reported second-quarter 2026 total revenue of $2.7 billion, up 3% from a year earlier, as growth products and the recently completed acquisition of Apellis contributed to results. Core pharmaceutical revenue rose 4% year over year to $1.8 billion, while the company's growth portfolio generated more than $1 billion in quarterly revenue, up 24% from the prior-year period.
Biogen Inc. (BIIB) came out with quarterly earnings of $3.6 per share, beating the Zacks Consensus Estimate of $3.04 per share. This compares to earnings of $5.47 per share a year ago.
Biogen's second-quarter profit plummeted and the biopharmaceutical company cut its full-year adjusted earnings forecast.
Biogen reported second-quarter profit and revenue that topped Wall Street estimates on Wednesday, driven by strong demand for its rare-disease medicines, while sales of its legacy multiple sclerosis drugs stayed under pressure.
Biogen's growth portfolio, which includes one closely watched Alzheimer's drug, is a bright spot in the second quarter.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on BIIB and any ticker you trade — then tracks every position and per-strategy win rate.
